Type 2 Diabetes
Conditions
Keywords
type 2 diabetes, gut microbiota, sitagliptin
Brief summary
The present study will recruit 9 newly diagnosed type 2 diabetic patient to receive sitagliptin 100mg daily for 12 weeks. The aim of this study was to investigate the composition of gut microbiota before and after the therapy of sitagliptin.
Detailed description
The present study will included 9 newly diagnosed type 2 diabetic patient to receive sitagliptin 100mg daily for 12 weeks. These patients will receive 75g oral glucose tolerance test and fasting plasma glucose levels, lipids levels, fasting insulin levels and 2 hour post-load plasma glucose levels will be measured. Stool samples will be collected before the initiation of the use of sitagliptin. After 12 weeks, all patients will have fasting plasma glucose levels, lipids levels, fasting insulin levels tested. Stool samples will be collected again.
Interventions
DRUGSitagliptin
All the patients will receive sitagliptin 100mg daily
Sponsors
Second Affiliated Hospital of Soochow University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Newly-diagnosed type 2 diabetic patients aged between 40-70 years
Exclusion criteria
* Any chronic disease (other than diabetes) * Alcohol consumption/smoking * Pregnancy/breastfeeding * The use of antibiotics, pro-prebiotics within 3 months * History of intestinal surgery
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The changes of the composition of gut microbiota before and after the use of sitagliptin | 12 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Changes of HbA1c levels | 12 weeks |
| Changes of fasting plasma glucose levels, lipids levels and insulin sensitivity | 12 weeks |
Outcome results
None listed